Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ONCT Oncternal Therapeutics, Inc. daily Stock Chart
ONCT [NASD]
Oncternal Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-4.27 Insider Own29.20% Shs Outstand15.36M Perf Week-18.91%
Market Cap42.99M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float11.31M Perf Month-22.03%
Income-36.60M PEG- EPS next Q- Inst Own17.70% Short Float0.33% Perf Quarter-20.36%
Sales2.50M P/S17.20 EPS this Y-101.10% Inst Trans85.81% Short Ratio0.92 Perf Half Y-47.65%
Book/sh0.68 P/B3.28 EPS next Y- ROA-153.50% Target Price- Perf Year-61.68%
Cash/sh- P/C- EPS next 5Y0.00% ROE-222.70% 52W Range2.24 - 6.29 Perf YTD-43.54%
Dividend- P/FCF- EPS past 5Y37.10% ROI-231.50% 52W High-64.55% Beta1.25
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low-0.45% ATR0.28
Employees11 Current Ratio2.30 Sales Q/Q20.00% Oper. Margin- RSI (14)30.79 Volatility9.22% 9.96%
OptionableNo Debt/Eq0.00 EPS Q/Q50.60% Profit Margin- Rel Volume3.90 Prev Close2.48
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume40.60K Price2.23
Recom3.00 SMA20-22.01% SMA50-21.23% SMA200-42.87% Volume158,444 Change-10.08%
Jun-30-20 08:00AM  
Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia
Business Wire
07:45AM  
Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma
Business Wire
May-20-20 08:00AM  
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Business Wire
May-19-20 08:00AM  
Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting
Business Wire +23.17%
May-07-20 08:00AM  
Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results
Business Wire -5.87%
May-05-20 08:00AM  
Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update
Business Wire
May-01-20 08:00AM  
Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update
Business Wire
Mar-18-20 08:36AM  
Is Oncternal Therapeutics (NASDAQ:ONCT) In A Good Position To Invest In Growth?
Simply Wall St. -10.01%
Mar-16-20 04:05PM  
Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results
Business Wire
Mar-11-20 04:08PM  
Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update
Business Wire +12.20%
08:00AM  
Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
Business Wire
Feb-06-20 08:00AM  
Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Business Wire
Dec-12-19 06:00PM  
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium
Business Wire
Dec-11-19 08:00AM  
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma
Business Wire -10.62%
Dec-09-19 08:00AM  
Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting
Business Wire
Dec-03-19 08:00AM  
Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium
Business Wire
Nov-21-19 08:00AM  
Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference
Business Wire
Nov-14-19 04:02PM  
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting
Business Wire
Nov-11-19 08:00AM  
Oncternal Therapeutics to Present at Stifel Healthcare Conference
Business Wire +5.74%
Nov-07-19 04:05PM  
Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update
Business Wire
Nov-05-19 08:00AM  
Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting
Business Wire +8.80%
Oct-31-19 08:00AM  
Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update
Business Wire
Oct-03-19 08:00AM  
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
Business Wire
Sep-20-19 12:03PM  
We're Not Very Worried About Oncternal Therapeutics's (NASDAQ:ONCT) Cash Burn Rate
Simply Wall St.
Sep-17-19 04:05PM  
Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Childrens Oncology Group Meeting
Business Wire -5.70%
Sep-09-19 08:00AM  
Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer
Business Wire
Aug-28-19 04:01PM  
Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing
Business Wire
Aug-08-19 04:01PM  
Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update
GlobeNewswire
Aug-06-19 08:00AM  
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib
GlobeNewswire +5.75%
Aug-01-19 04:01PM  
Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
GlobeNewswire -5.29%
Jun-10-19 08:00AM  
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
GlobeNewswire -16.31%
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.
open in yahoo | open in reuters | open in google